Targeted therapy in Bile duct cancers


Mike Cusnir MD

Division Chief Hematology and Oncology


Miami Beach, Florida

BRAMANCOMESSION

Mount Sinai MEDICAL CENTER



Outcomes in Patients with Biliary Tract Cancer Who Received Gemcitabine Alone versus Cisplatin plus Gemcitabine.



OS:

- 11.7 months cisplatin– gemcitabine
- 8.1 months gemcitabine group (hazard ratio, 0.64; 95% confidence interval, 0.52 to 0.80; P<0.001)



Target therapies



Infectious disease

1800

- Mercury Beta-Lactamase
- Arsenic

- 1950
- Protease inh

Oncology

2020

- Platinum Proteosome inh
- Arsenic Immunotherapy

2000

• Etc Target du jour

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Hazard Ratio

(95% CI)

0.80 (0.66-0.97)

18

21

15

39 29 24

Stratified Log-rank

P Value


0.021

Durva + Gem + Cis

24


27

0 0



Oh D-Y et al. NEJM Evid2022;1:EVIDoa2200015

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966)



Kelley, Robin KateAkce, Mehmet et al. The Lancet, Volume 401, Issue 10391, 1853 - 1865

TOPAZ-1

KEYNOTE 966

Subgroup		Durva + Gem + Cis No. of events/Total no. (%)	Placebo + Gem + Cis No. of events/Total no. (%)	Hazard Ratio (95% CI
All patients	H.	198/341 (58.1%)	226/344 (65.7%)	0.80 (0.66-0.97)
Sex: female	⊢ ● I	99/172 (57.6%)	104/168 (61.9%)	0.82 (0.62-1.08)
Sex: male	⊢ ●–	99/169 (58.6%)	122/176 (69.3%)	0.78 (0.60-1.01)
Age at randomization: <65 yr	⊢ ●	100/181 (55.2%)	116/184 (63.0%)	0.80 (0.61-1.04)
Age at randomization: ≥65 yr	⊢• I	98/160 (61.3%)	110/160 (68.8%)	0.79 (0.60-1.04)
PD-L1 expression: TAP ≥1%	⊢ ●−1	120/197 (60.9%)	138/205 (67.3%)	0.79 (0.61-1.00)
PD-L1 expression: TAP <1%		57/103 (55.3%)	66/103 (64.1%)	0.86 (0.60-1.23)
Disease status at randomization: initially unresectable		176/274 (64.2%)	194/279 (69.5%)	0.84 (0.69-1.03)
Disease status at randomization: recurrent	⊢I	22/67 (32.8%)	32/64 (50.0%)	0.56 (0.32-0.96)
Primary tumor location: intrahepatic cholangiocarcinoma	H • 1	105/190 (55.3%)	126/193 (65.3%)	0.76 (0.58-0.98)
rimary tumor location: extrahepatic cholangiocarcinoma	H	38/66 (57.6%)	42/65 (64.6%)	0.76 (0.49-1.19)
rimary tumor location: gallbladder cancer		55/85 (64.7%)	58/86 (67.4%)	0.94 (0.65-1.37)
ace: Asian	H	107/185 (57.8%)	141/201 (70.1%)	0.73 (0.57-0.94)
ace: non-Asian	 • 	91/156 (58.3%)	85/143 (59.4%)	0.89 (0.66-1.19)
egion: Asia	⊢ ●−1	103/178 (57.9%)	137/196 (69.9%)	0.72 (0.56-0.94)
egion: rest of the world	 -+ +	95/163 (58.3%)	89/148 (60.1%)	0.89 (0.66-1.19)
COG performance status at baseline: 0		95/173 (54.9%)	93/163 (57.1%)	0.90 (0.68-1.20)
COG performance status at baseline: 1	H •-1	103/168 (61.3%)	133/181 (73.5%)	0.72 (0.56-0.94)
iliary tract cancer: locally advanced	<u> </u>	16/38 (42.1%)	36/57 (63.2%)	0.49 (0.26-0.88)
iliary tract cancer: metastatic			190/286 (66.4%)	0.83 (0.68-1.02)
o.os o.1	0.5 1 1 Hazard Ratio (95% CI)	182/303 (60.1%)	130/200 (06.476)	0.05 (0.06-1.02)
0.05 0.1 3		Durva + Gem + Cis	Placebo + Gem + Cis	
0.05 0.1 3 Subgroup		Durva + Gem + Cis No. of events/Total no. (%)	Placebo + Gem + Cis No. of events/Total no. (%)	Hazard Ratio (95% CI
0.05 0.1 B Subgroup Il patients		5 2 Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%)	Hazard Ratio (95% Cl 0.75 (0.63-0.89)
0.05 0.1 B ubgroup Il patients ex: female		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99)
0.05 0.1 3 Jubgroup Jul patients ex: female ex: male		5 2 Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 151/176 (85.8%)	Hazard Ratio (95% Cl 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93)
0.05 0.1 B ubgroup II patients ex: female ex: male ge at randomization: <65 yr		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 151/176 (85.8%) 159/184 (86.4%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85)
0.05 0.1 Bubgroup Il patients ex: female ex: male ge at randomization: <65 yr ge at randomization: ≥65 yr		5 2 Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 151/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07)
0.05 0.1 ubgroup II patients ex: female ex: male ge at randomization: <65 yr ge at randomization: ≥65 yr D-L1 expression: TAP ≥1%		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 159/184 (86.4%) 159/184 (86.4%) 138/160 (86.3%) 179/205 (87.3%)	Hazard Ratio (95% Cl 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91)
0.05 0.1 3 3 3 4 4 4 4 4 4 4 4 5 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 151/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 138/160 (86.3%) 87/103 (84.5%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09)
0.05 0.1 S ubgroup Il patients ex: female ex: male ge at randomization: <65 yr ge at randomization: <65 yr D-L1 expression: TAP ≥1% D-L1 expression: TAP ≥1% Usease status at randomization: initially unresectable		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 151/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 179/205 (87.3%) 87/103 (84.5%) 247/279 (88.5%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.73 (0.52–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.66–0.95)
0.05 0.1 B ubgroup Il patients ex: female ex: male ge at randomization: <65 yr ge at randomization: ≥65 yr D-L1 expression: TAP <1% D-L1 expression: TAP <1% D-L1 expression: TAP <1% D-L1 expression: TAP <1%		5 2 Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 155/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 179/205 (87.3%) 87/103 (84.5%) 247/279 (88.5%) 50/64 (78.1%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.66–0.95) 0.63 (0.42–0.94)
0.05 0.1 S Subgroup Il patients ex. female ex. male ex. male ge at randomization: >65 yr D-L1 expression: TAP ≥1% D-L1 expression: TAP >1% D-L1 expression: TAP >1%		5 2 Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 155/176 (85.9%) 155/174 (86.4%) 138/160 (86.3%) 179/205 (87.3%) 87/103 (84.5%) 247/279 (88.5%) 50/64 (78.1%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.66–0.95) 0.63 (0.42–0.54) 0.79 (0.64–0.99)
0.05 0.1 Augroup Il patients ex: female ex: male ge at randomization: <65 yr ge at randomization: 265 yr D-L1 expression: TAP <1% D-L1 expression: TAP <1% D-L1 expression: TAP <1% D-L1 expression: TAP <1% Disease status at randomization: initially unresectable bisease status at randomization: recurrent rimary turnor location: intrahepatic cholangiocarcinoma rimary turnor location: extrahepatic cholangiocarcinoma		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%) 50/66 (75.8%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 151/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 179/205 (87.3%) 87/103 (84.5%) 247/279 (88.5%) 50/64 (78.1%) 167/193 (86.5%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.66–0.95) 0.63 (0.42–0.94) 0.79 (0.64–0.99) 0.52 (0.35–0.78)
0.05 0.1 Autor of the set of the		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%) 50/66 (75.8%) 72/85 (84.7%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 151/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 247/279 (88.5%) 247/279 (88.5%) 50/64 (78.1%) 167/193 (86.5%) 55/55 (84.6%) 75/86 (87.2%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.73 (0.62–0.99) 0.73 (0.58–0.33) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.66–0.95) 0.63 (0.42–0.39) 0.79 (0.64–0.99) 0.52 (0.35–0.78) 0.90 (0.65–1.24)
0.05 0.1 B Bubgroup II patients ex: female ex: male ex: male ge at randomization: <65 yr ge at randomization: 265 yr D-L1 expression: TAP <1% D-L1 expression:		5 2 Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%) 50/66 (75.8%) 72/85 (84.7%) 147/185 (79.5%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 155/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 179/205 (87.3%) 87/103 (84.5%) 247/279 (88.5%) 50/64 (78.1%) 167/193 (86.5%) 55/65 (84.6%) 75/56 (87.2%) 179/201 (89.1%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.64–0.95) 0.63 (0.42–0.94) 0.79 (0.64–0.99) 0.52 (0.35–0.78) 0.90 (0.65–1.24) 0.67 (0.54–0.83)
0.05 0.1 abgroup Il patients ex: female ex: male ge at randomization: <65 yr ge at randomization: <65 yr D-L1 expression: TAP ≥1% D-L1 expr		5 2 Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%) 50/66 (72.6%) 72/85 (84.7%) 147/185 (79.5%) 129/156 (82.7%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 155/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 179/205 (87.3%) 87/103 (84.5%) 247/279 (88.5%) 50/64 (78.1%) 167/193 (86.5%) 55/56 (84.6%) 75/86 (87.2%) 119/201 (89.1%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.79 (0.66–0.95) 0.63 (0.42–0.94) 0.79 (0.64–0.99) 0.52 (0.35–0.78) 0.90 (0.65–1.24) 0.67 (0.54–0.83) 0.88 (0.69–1.14)
0.05 0.1 Abgroup Il patients ex: female ex: male ge at randomization: <65 yr ge at randomization: 265 yr D-L1 expression: TAP ≥1% D-L1 expression: TAP >1% D-L1 expression: TAP >1% D-L1 expression: TAP >1% D-L1 ex		5 2 Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%) 50/66 (75.8%) 72/88 (84.7%) 147/185 (79.5%) 129/156 (82.7%) 129/156 (82.7%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 155/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 247/279 (88.5%) 247/279 (88.5%) 250/64 (78.1%) 167/193 (86.5%) 55/65 (84.6%) 75/56 (87.2%) 179/201 (89.1%) 118/143 (82.5%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.64–0.95) 0.63 (0.42–0.94) 0.79 (0.64–0.99) 0.52 (0.35–0.78) 0.90 (0.65–1.24) 0.67 (0.54–0.83) 0.88 (0.69–1.14)
0.05 0.1 Autor of the world O.05 0.1 O.05 0.1 O.05 0.1 O.05 O.1 O.05 O.1 O.1 O.1 O.1 O.1 O.1 O.1 O.1		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%) 50/66 (75.8%) 72/85 (84.7%) 147/185 (79.5%) 129/156 (82.7%) 142/178 (79.8%) 134/163 (82.2%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 115/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 247/279 (88.5%) 207/103 (84.5%) 247/279 (88.5%) 50/64 (78.1%) 167/193 (86.5%) 55/55 (84.6%) 75/86 (87.2%) 179/201 (89.1%) 118/143 (82.5%) 174/196 (88.8%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.66–0.95) 0.63 (0.42–0.94) 0.79 (0.64–0.99) 0.52 (0.35–0.78) 0.90 (0.65–1.24) 0.67 (0.54–0.83) 0.88 (0.69–1.14) 0.67 (0.54–0.83) 0.87 (0.68–1.12)
0.05 0.1 3 3 3 3 3 3 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/166 (79.3%) 144/181 (79.6%) 132/166 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%) 50/66 (75.8%) 72/85 (84.7%) 147/185 (79.5%) 129/156 (82.7%) 134/163 (82.2%) 134/163 (82.2%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 151/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 247/279 (88.5%) 247/279 (88.5%) 50/64 (78.1%) 167/193 (86.5%) 55/65 (84.6%) 75/586 (87.2%) 179/201 (89.1%) 118/143 (82.5%) 118/143 (82.5%) 123/148 (83.1%) 123/148 (83.1%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.33) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.64–0.95) 0.63 (0.42–0.94) 0.79 (0.64–0.99) 0.52 (0.35–0.78) 0.90 (0.65–1.24) 0.67 (0.54–0.83) 0.88 (0.69–1.14) 0.67 (0.54–0.83) 0.87 (0.68–1.12) 0.77 (0.61–0.98)
0.05 0.1 3 3 3 3 3 4 4 4 5 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5		5 2 Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/169 (79.3%) 144/181 (79.6%) 132/160 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%) 50/66 (73.8%) 72/85 (84.7%) 147/185 (79.5%) 129/156 (82.7%) 142/178 (79.8%) 134/163 (82.2%) 140/173 (80.9%) 136/168 (81.0%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 155/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 179/205 (87.3%) 87/103 (84.5%) 247/279 (88.5%) 247/279 (88.5%) 50/64 (78.1%) 167/193 (86.5%) 55/55 (86.6%) 75/86 (87.2%) 118/143 (82.5%) 118/143 (82.5%) 118/143 (83.1%) 140/163 (85.5%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.79 (0.66–0.95) 0.63 (0.42–0.94) 0.79 (0.64–0.99) 0.52 (0.35–0.78) 0.90 (0.65–1.24) 0.67 (0.54–0.83) 0.88 (0.69–1.14) 0.67 (0.53–0.83) 0.87 (0.68–1.12) 0.77 (0.61–0.98) 0.76 (0.60–0.95)
0.05 0.1 A balance of the world COG performance status at baseline: 0 0.05 0.1 0.05 0.1 0.		Durva + Gem + Cis No. of events/Total no. (%) 276/341 (80.9%) 142/172 (82.6%) 134/166 (79.3%) 144/181 (79.6%) 132/166 (82.5%) 160/197 (81.2%) 82/103 (79.6%) 228/274 (83.2%) 48/67 (71.6%) 154/190 (81.1%) 50/66 (75.8%) 72/85 (84.7%) 147/185 (79.5%) 129/156 (82.7%) 134/163 (82.2%) 134/163 (82.2%)	Placebo + Gem + Cis No. of events/Total no. (%) 297/344 (86.3%) 146/168 (86.9%) 151/176 (85.8%) 159/184 (86.4%) 138/160 (86.3%) 247/279 (88.5%) 247/279 (88.5%) 50/64 (78.1%) 167/193 (86.5%) 55/65 (84.6%) 75/586 (87.2%) 179/201 (89.1%) 118/143 (82.5%) 118/143 (82.5%) 123/148 (83.1%) 123/148 (83.1%)	Hazard Ratio (95% CI 0.75 (0.63–0.89) 0.78 (0.62–0.99) 0.73 (0.58–0.93) 0.68 (0.54–0.85) 0.84 (0.66–1.07) 0.73 (0.59–0.91) 0.80 (0.59–1.09) 0.79 (0.64–0.95) 0.63 (0.42–0.94) 0.79 (0.64–0.99) 0.52 (0.35–0.78) 0.90 (0.65–1.24) 0.67 (0.54–0.83) 0.88 (0.69–1.14) 0.67 (0.54–0.83) 0.87 (0.68–1.12) 0.77 (0.61–0.98)

	Events/participants		Hazard ratio (95%
	Pembrolizumab plus gemcitabine and cisplatin	Placebo plus gemcitabine and cisplatin	
Age (years)			
<65	210/269	242/298	0.88 (0.73-1.05)
≥65	204/264	201/238	0.79 (0.65-0.97)
Sex			
Female	200/253	220/264	0.85 (0.70-1.03)
Male	214/280	223/272	0.83 (0.69-1.00)
Geographical region			
Asia	185/242	201/244	0.88 (0.72-1.08)
Not Asia	229/291	242/292	0.80 (0.67-0.96)
ECOG performance st	atus		1 · · · · ·
0	186/258	177/228	0.87 (0.71-1.07)
1	227/274	266/308	0.84 (0.70-1.00)
Smoking status			
Current	42/56	38/49	0.90 (0.58-1.40)
Former	160/205	160/191	0.87 (0.70-1.09)
Never	212/272	244/295	0.82 (0.68-0.98)
Antibiotic use within	1 month of study start		
No	364/471	403/493	- 0.85 (0.73-0.97)
Yes	50/62	40/43	0.72 (0.47-1.09)
Site of origin			
Extrahepatic	78/98	83/105	0.99 (0-73-1-35)
Gallbladder	102/115	104/118	0.96 (0.73-1.26)
Intrahepatic	234/320	256/313	0.76 (0.64-0.91)
Disease status			
Locally advanced	37/60	52/66	0.69 (0.45-1.06)
Metastatic	377/473	391/470	0.85 (0.74-0.98)
Biliary stent or drain	511145		
No	388/500	406/495	0.85 (0.74-0.98)
Yes	26/33	37/41	0.72 (0.43-1.19)
Previous chemothera	DA 1	•	
No	382/483	408/488	0.86 (0.75-0.99)
Yes	32/50	35/48	0.66 (0.41-1.08)
PD-L1 combined posi		*	
<1	86/113	87/110	0.84 (0.62-1.14)
>1	287/363	309/365	0.85 (0.72-1.00)
Unknown	41/57	47/61	0.77 (0.51-1.18)
Overall	414/533	443/536	0-83 (0-72-0-95)
			0.03 (0.12-0.33)

Favours pembrolizumab plus gemcitabine and cisplatin Favours placebo plus gemcitabine and cisplatin

Standard of Care in Advanced BTCs

GemCis (GC), gemcitabine/cisplatin; 1L, first-line; 2L, second-line; FOLFOX, fuluorouracil/leucovorin/oxaliplatin; nal-IRI, liposomal irinotecan; FF, leucovorin/fuluorouracil; BSC, best supportive care; CAP, capecitabine; S-1, tegafur/gimeracil/oteracil; ORR, objective response rate; D, durvalumab.

- GemCis has been the standard 1L chemotherapy since the results of the ABC-02 trial were reported.¹ Recently, the survival benefit of additional durvalumab was demonstrated in TOPAZ-1 trial.²
- Concerning 2L chemotherapy, FOLFOX³ and nal-IRI + FF⁴ have demonstrated superiority over BSC or FF, and fluoropyrimidine monotherapy (e.g., CAP, S-1⁵) is a treatment option.
- These cytotoxic regimens and agents for BTCs in the 2L setting have modest activity with an ORR of 5–15%.

1L se	etting	2L setting			
GC	GC + D	FOLFOX	nal-IRI + FF	S-1	
18.7	26.7	5.0	14.8	7.5	
5.7	7.2	4.0	7.1	2.5	
11.5	12.8	6.2	8.6	6.8	
	GC 18.7 5.7	18.7 26.7 5.7 7.2	GCGC + DFOLFOX18.726.75.05.77.24.0	GC GC + D FOLFOX nal-IRI + FF 18.7 26.7 5.0 14.8 5.7 7.2 4.0 7.1	

1. NEJM 2010;362:1273. 2. JCO 2022;40(suppl):378. 3. Lancet Oncol 2021;22:690. 4. Lancet Oncol 2021;22:1560. 5. Cancer Chemother Pharmacol 2013;71:1141.

Printed by Mike Cusnir on 3/30/2025 7:35:28 AM. For personal use only. Not approved for distribution. Copyright @ 2025 National Comprehensive Cancer Network, Inc., All Rights Reserved.


	SYSTEMIC THERAPY ^{a,k}	NCCN Guidelines Index Table of Contents Discussion	the second secon
Primary Treatment for Unresectable and Metastatic Disease Useful in Certain Circumstances	TED THERAPY		
 For NTRK gene fusion-positive tumors: Entrectinib^{13,14} Larotrectinib¹⁵ Repotrectinib¹⁶ For MSI-H/dMMR tumors: Pembrolizumab^{9,1,17-20} For TMB-H tumors: Nivolumab + ipilimumab (category 2B)^{9,21} For RET gene fusion-positive tumors: Pralsetinib (category 2B)²² Selpercatinib (category 2B)²³ 2/2 	 Next Slide 		C C C C C C C C C C C C C C
Subsequent-Line Therapy for Biliary Tract Cancers if Disease Prog Useful in Certain Circumstances	ression ⁱ		20- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 For NTRK gene fusion-positive tumors^m: Entrectinib^{13,14} Larotrectinib¹⁵ Repotrectinib¹⁶ For MSI-H/dMMR tumors: Pembrolizumab^{9,h,l,17-20} Dostarlimab-gxly (category 2B)^{9,h,n,24} For TMB-H tumors: Nivolumab + ipilimumab^{9,h,0,21} Pembrolizumab^{9,h,l,17,25} For BRAF V600E-mutated tumors Dabrafenib + trametinib^{26,27} For NTRK gene fusion-positive tumors^m: For MER2-positive tumors Fam-trastuzumab deruxt Trastuzumab + pertuzum Tucatinib + trastuzumab Zanidatamab-hrii (IHC3+) 	ns ³² ecan-nxki (IHC3+) ³³ ab (IHC3+/ISH+/NGS amplification) ³⁴ (IHC3+/ISH+/NGS amplification) ³⁵		Nomber et risk 31.05) 28 (14) 17 (19) 12 (7) 9 (6) 5 (4) 3 (3)
 ^a Order does not indicate preference. ^g See <u>NCCN Guidelines for Management of Immunotherapy-Related Toxicities</u>. ^h For patients who have not been previously treated with a checkpoint inhibitor when used as subsequent-line therapy because there is a lack of data for use immunotherapy in patients who have previously been treated with a checkpoin inhibitor. ⁱ Treatment selection depends on clinical factors including previous treatment regimen/agent, somatic molecular testing results, and extent of liver dysfunctions. ^k An FDA-approved biosimilar is an appropriate substitute for any recommender systemic biologic therapy in the NCCN Guidelines. 	there was progression on prior of ⁿ Dostarlimab-gxly is a recomme dMMR recurrent or advanced t treatment and who have no sa ^o For patients with disease refra standard treatment options ava	ended treatment option for patients with MSI-H/ tumors that have progressed on or following prior tisfactory alternative treatment options. ctory to standard therapies or who have no ailable. a preferred over erdafitinib.	


- standard treatment options available.
- ^p Futibatinib and pemigatinib are preferred over erdafitinib.
 ^q The data available for this agent are from a smaller trial.
 <u>References on BIL-C 4 of 5</u>

MSI-H Cholangiocarcinoma

Type of BTC	Frequency, % (n)	Study	Year of report
Intrahepatic cholangiocarcinoma	18.2% (4/22)	(6)	2001
Intrahepatic cholangiocarcinoma	4.7% (1/23)	(7)	2002
Ampullary carcinoma	5.6% (3/54)	(8)	2010
Gallbladder carcinoma	7.8% (6/77)	(9)	2015
Cholangiocarcinoma	1.4% (1/74)	(10)	2017
Biliary tract cancer	2.1% (8/375)	(11)	2018
Biliary tract cancer	0% (0/99)	(12)	2018

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies






Intl Journal of Cancer, Volume: 147, Issue: 8, Pages: 2190-2198, First published: 02 May 2020, DOI: (10.1002/ijc.33013)

Intrahepatic Cholangiocarcinoma						
Classification	Small Duct Type	Large Duct Type				
Gross Type	Mass-forming Mix	ked Periductal Infiltrating				
Cell of Origin						
	Canal of Hering Bile ductule	Columnar cholangiocytes Peribiliary glands				
Main Etiology	Chronic hepatitis HBV / HCV Alcoholic / Metabolic	Hepatolithiasis Liver fluke PSC				
Immuno- histochemistry & Mucin stain	NCAM N-cadherin CRP	S100P Mucin				
Frequent Mutations	BAP1 IDH1/2 FGFR2 fusion	KRAS TP53 SMAD4				
Suggested Molecular Classification*	Inflammation Class	Proliferation Class				
Patient Outcome	Favorable	Poor				

Front. Med., 31 March 2022







Journal of Hepatology 2020 73170-185DOI: (10.1016/j.jhep.2020.03.007)


Terms and Conditions


CCA type	Gross pattern	Precancerous lesion	Underlying disease	Tissue markers ^a	Frequent mutations
icca — CLC	Mass-forming	None	Viral, cirrhosis	NCAM	IDH1/2, FGFR2 fusions, BAP1, BRAF, ARID1A, KRAS, TP53, SMAD4 Increased IDH1 and TP53
iCCA — small duct type	Mass-forming	None	Viral, cirrhosis	NCAM, N-cadherin, SMAD4, BAP1 ^{loss}	IDH1/2, FGFR2 fusions, BAP1, BRAF, ARID1A, KRAS, TP53, SMAD4 Increased IDH1/2, FGFR2 fusion
iCCA — large duct type	Periductal infiltrating (±mass- forming) or intraductal growing	Biliary epithelial neoplasia, IPNB, ITPN, mucinous cystic neoplasm	Primary sclerosing cholangitis, liver flukes	Mucin ^b , MUC5AC, MUC6, S100P, SMAD4 ^{loss} , BAP1	IDH1/2, FGFR2 fusions, BAP1, BRAF, ARID1A, KRAS, TP53, SMAD4 Increased KRAS and TP53
pCCA–dCCA	Periductal infiltrating or intraductal growing	Biliary epithelial neoplasia, IPNB, ITPN, mucinous cystic neoplasm	Primary sclerosing cholangitis, liver flukes	Mucin ^b , MUC5AC, MUC6, S100P, SMAD4 ^{loss} , BAP1	KRAS, TP53, SMAD4, ERBB3, PRKACA–PRKACB fusions, ELF3

CCA, cholangiocarcinoma; CLC, cholangiolocarcinoma; dCCA, distal cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; IPNB, intraductal papillary neoplasm of the bile duct; ITPN, intraductal tubulopapillary neoplasm; pCCA, perihilar cholangiocarcinoma. ^aMarkers from single-centre experience; international criteria and consensus on a definite panel of markers are still needed. ^bMucin refers to histomorphological stains periodic acid–Schiff (PAS) or Alcian PAS.


Nature Reviews Gastroenterology & Hepatology volume 17, pages 557–588 (2020)

Dabrafenib plus trametinib in patients with *BRAF*^{V600E}-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial






The Lancet VOLUME 21, ISSUE 9, P1234-1243, SEPTEMBER 01, 2020



Nature Reviews Gastroenterology & Hepatology volume 17, pages 557–588 (2020)







Journal of Hepatology 2020 73170-185DOI: (10.1016/j.jhep.2020.03.007)

Terms and Conditions

Changes in genetic expression






From: Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial


JAMA Oncol. Published online September 23, 2021. doi:10.1001/jamaoncol.2021.3836

JAMA Oncology

RCT: Efficacy of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation




Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation




Progression-free survival

Key results




Abou-Alfa, Ghassan K et al. The Lancet Oncology, Volume 21, Issue 6, 796 - 807

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomize



Treatment group	Events/patients, No.	OS, median (95% CI), mo		
Ivosidenib	100/126	10.3 (7.8-12.4)		
Placebo	50/61	7.5 (4.8-11.1)		
Placebo adjusted by RPSFT	49/61	5.1 (3.8-7.6)		







Journal of Hepatology 2020 73170-185DOI: (10.1016/j.jhep.2020.03.007)

Terms and Conditions

Table 1. Current status of development of FGFR2 inhibitors in iCCA.

Drug; Author, reference	Type of molecule	Current status of drug development	CCA population tested	Treatment administered	Response rate achieved	Treatment-related	toxicity				
Pemigatinib- INC8054828 (Incyte®) ^{145,146}	Selective oral TKI Target: FGFR 1-3 and VEGFR2.	Phase II study (FIGHT-202; NCT02924376) presented ESMO ¹⁴⁵ 2018 with updated data ESMO 2019. ¹⁴⁶ Ongoing Phase III trial in the first-line setting (FIGHT-302; NCT03656536).	Previously treated CCA (146 patients). Cohort A (<i>RGFR2</i> fusions): 107 patients (98% iCCA; 93% 22 prior therapies) Cohort B (other FGF/ FGFR alterations): 20 patients (65% iCCA). Cohort C (no FGF/FGFR alterations): 18 patients (61% iCCA)	INCB054828 13.5 mg once daily on a 21-day cycle (2 weeks on, 1 week off) until disease progression or unacceptable toxicity.	Cohort A (FGFR2 trans- locations): ORR: 35.5% (3 CR), mDOR: 7.5 months, DCR: 82% mPFS 6.9 month (95% Cl 6.2–9.6) Cohort B (other FGC/FGFR alterations): 0% PR; mPFS 1.4 months* Cohort C (no FGC/FGFR alterations): 0% PR; mPFS 1.5 months*		7%), ' oxxicities a (40%). : and (7%)*. ;), dose				
Infigratinib- BCJ398 (QED®/ Novartis®) ^{139,147}	Selective oral TKI Target: FGFR 1-3 (IC50 0.9, 1.4 and 1 nM, respectively)/ FGFR4 (IC50 60 nM).	Phase II study (NCTD2150967) published in 2018 ¹³⁹ with updated data (+28 patients with FGFR2 fusion) presented ESMO 2018. ¹⁴⁷ Ongoing Phase III trial in the first-line setting (PROOF; NCT03773302).	Previously treated CCA (61 patients → 84 ⁵) FGFR2 fusions: 48 patients → expanded up to 71 patients ¹⁸⁷³ • FGFR2 mutation: 8 patients • FGFR2 amplification: 3 patients	daily for 21 days, then	 PR: 14.8%; DCR: 75.4% FGFR2 fusions: 18.8% PR; DCR 83.3%; mPFS 5.8 months (9% CI 4.3–7.6) → expanded cohort²; 31.0% PR: DCR 83.6%, mPFS 6.8 months (95% CI 5.3–7.6 FGFR2 mutation: 0% PR FGFR2 amplification: 0% PR 	(14.1%5), mucositis (29.5%),). 2%): (16.4%/ hatemia 6.6%), and (4.9%). grade grade hatemia 3%), alopecia				
TAS-120 (futibatinib)	Highly selective (irreversible) oral TKI	Safety and preliminary effi- cacy data available from	Cohort of pretreated CCA (45 patients) harbouring	TAS-120 (maximum tolerated dose defined	 FGFR2 fusions: 25% PR; SD 54%; DCR: 79% 	Drug; Author, reference	Type of molecule	Current status of drug development	CCA population tested	Treatment administered	Response rate achieved
(Taiho®) ^{145,149}	Target: FGFR 1-4 (inhibits all 4 subtypes of FGFR with enzyme IC50 values of 3.9 nM, 1.3 nM, 1.6 nM and 8.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively) Inhibits mutant and wild-type FGFR2 with similar IC50 (wild-type FGFR2, 0.9 nM; V5651, 1-3 nM; N550H, 3.6 nM; E566G, 2.4 nM).	ESMO Asia and ESMO GI 2018) (NCT02052778); phase	FGF/FGFR aberrations. • FGFR2 gene fusions: 28 patients (62%) • Other FGF/FGFR aberrations: 17 (38%) 13 patients received ≥1 prior reversible FGFRi.	as 20 mg once a day) until disease progres- sion or unacceptable toxicity. CCA pts were enrolled at 16 mg (24 patients), 20 mg (14 patients), and 24 mg (7 patients) dosing levels.	 Other FGF/FGR aberration: 3/17 (17.6%) PR (all had FGFR2 rearrangements; 1 also had FGR2 amplification) Prior FGFRi: 4/13 (30.8%) P (3 with FGFR2 gene fusion: 1 with FGFR2 amplification 	Derazantinib (Basilea/ ArQule®) ^{140,150}	Non-selective oral multi-TKI with potent pan-FGFR activity. Targets: RET, PDGFR, KIT, SRC, and FGFR1-3 (IC50 1.8 for FGFR2 IC50 4.5 for FGFR1 and FGFR3), IC50 for FGFR4 34 nM.	Preliminary data from the phase 1/II basket trial indicated activity in FGR2 fusion-positive iCCA (3/12 (25%) PR) (NCID1752920). ¹⁴⁰ Data for iCCA with FGR2 fusion were separately reported. ¹⁵⁰ Currently being evaluated in a phase II trial in iCCA (FIDES-01 trial;	Pretreated iCCA patients (35 patients) with FGFR2 genetic aberrations. 29/35 patients had FGFR2 fusion-positive tumours.	ARQ087 300 (33 patients) or 400 mg (2 patients) daily until disease progression or unacceptable toxicity. Recommended phase II dose: 300 mg QD. ¹⁶³	 30 patients evaluable for response: 20% PR (all FGR2 fusion-positive) FGFR2 fusion-positive patients⁴: 20.7% PR; 82.8% DCR, mPFS 5.7 months.
						Debio1347	Selective oral TKI	NCT03230318). Safety shown in phase I trial	Patients with pretreated	Debio 1347 at doses	• 1/8 PR (FGFR2 deletion);
						(Debioph arm Group ®) ^{151,152}	Target: FGFR 1-3 (IC50 of 9.3 nM, 76 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively).	(NCT1948297), CCA data re- ported by Cleary <i>et al.</i> ¹⁵¹ and Ng 2019. ⁵⁵² Currently phase II basket trial ongoing recruiting patients with <i>FGFR1-3</i> fusions (tumour-agnostic) (FUZE trial; NCT03834220).	biliary tract (iCCA (6 pa- tients; 3 FGFR2 fusion) and GBC (2 patients; none with FGFR2 fusions) with alterations of FGFR 1, 2, or 3. Separately, data on 9 CCA ¹⁵² (all iCCA; 5 FGFR2 fusion) were reported ⁸ .	between 60 and 150 mg orally daily in 28-day cycles until disease progression or	DCR 62.5%.
						JNJ-42756493- Erdafitinib (Janssen®) ^{153,154}	Selective oral TKI Target: FGFR 1-4 (IC50 <1 nM).	Phase I trial data available (NCT01703481); new trial ongoing and recruiting cohort of cholangiocarcinoma (NCT02699606).	Patients with re-treated solid tumours harbouring activating <i>FGFR</i> genomic alterations (187 patients; 11 CCA).	JNJ-42756493-dose escalation: 9 mg once daily and 10 mg intermittently (7 days on/7 days off), as previously published. ¹⁸⁷	 CCA cohort in response evaluable patients with <i>RGFR</i> mutation/fusion: 27.3% (3/11) PR (all at 10 mg dose). Updated data[®]: mDOR 12.9 months; DCR: 55%; mPFS: 5.1 months (1.6–1.6.4).

Data extracted from.^{139,140,145-154} IC50 data also extracted from.¹⁶²

AEs, adverse events; CCA, cholangiocarcinoma; CR, complete response; DCR, disease control rate; FGFR, fibroblast growth factor receptor; GBC, gallbladder cancer; IC50, half maximal inhibitory concentration; iCCA, intrahepatic cholangiocarcinoma; LFTs, liver function tests; mDOR, median duration of response; mPFS, median progression-free survival; PDGFR, platelet-derived growth factor receptor; PR, partial response; ORR, objective response rate; TEAEs, treatment-emergent adverse events; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.

Treatment-related toxicity

Any grade (89%): nausea

vomiting (23%), abnormal

alopecia (14%), diarrhoea (14%), vision blurred (14%), and conjunctivitis (11%). Grade 3/4: asthenia (6%), and abnormal LFTs (6%).

Any grade: hyper-

tis (3/8).

Grade ≥3: hyperphosphatemia (4/8); (33%[®]).

FGFR mutation/fusion: 27.3% dry mouth (55%), dysgeusia (3/11) PR (all at 10 mg dose). (45%), dry skin (45%), and Updated data[®]: mDOR 12.9 asthenia (45%)

months; DCR: 55%; mPFS: Grade ≥3[®]: stomatitis (18%).

phosphatemia (8/8), nail changes (5/8), nausea (5/8),

dry mouth (4/8) and stomati-

Any grade[®]: stomatitis (82%),

hyperphosphatemia (64%),

LFTs (20%), dysgeusia (20%),


(37%), dry mouth (29%), asthenia (26%), fatigue (23%),

*Data from,145


^{\$}Data from expanded FGFR2 fusion cohort patients.¹⁴⁷ [£]Data for patients with FGFR2 fusion only.¹⁵ Cohort of 9 patients with CCA.¹⁵²

[@]Updated data CCA cohort.¹⁵⁴

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202



(A) <u>FGFR2</u> rearrangements or fusions(B) other *FGF/FGFR* alterations(C) no *FGF/FGFR* alterations



ESMO Open Volume 9, Issue 6, June 2024, 103488

Events	FGFR2 fusions or rearrangements (n = 108)		Other FGF/FGFR alterations (n = 20)		No FGF/FGFR alterations (n = 17)		Total (N = 147) ^a	
	Any grade	Grade \geq 3	Any grade	Grade \geq 3	Any grade	Grade \geq 3	Any grade	Grade \geq 3
Any treatment-related TEAE, n (%) ^b	102 (94.4)	40 (37.0)	17 (85.0)	6 (30.0)	14 (82.4)	1 (5.9)	135 (91.8)	48 (32.7)
Hyperphosphatemia	55 (50.9)	0	11 (55.0)	0	12 (70.6)	0	79 (53.7)	0
Alopecia	61 (56.5)	0	3 (15.0)	0	2 (11.8)	0	68 (46.3)	0
Diarrhea	44 (40.7)	4 (3.7)	5 (25.0)	0	4 (23.5)	1 (5.9)	53 (36.1)	5 (3.4)
Stomatitis	43 (39.8)	9 (8.3)	4 (20.0)	0	3 (17.6)	0	51 (34.7)	9 (6.1)
Dysgeusia	42 (38.9)	0	3 (15.0)	0	3 (17.6)	0	50 (34.0)	0
Fatigue	38 (35.2)	2 (1.9)	4 (20.0)	0	6 (35.3)	0	48 (32.7)	2 (1.4)
Dry mouth	38 (35.2)	0	2 (10.0)	0	1 (5.9)	0	43 (29.3)	0
Nausea	32 (29.6)	2 (1.9)	2 (10.0)	0	3 (17.6)	0	38 (25.9)	2 (1.4)
Decreased appetite	25 (23.1)	0	5 (25.0)	1 (5.0)	4 (23.5)	0	35 (23.8)	1 (0.7)
Dry eye	33 (30.6)	0	0	0	0	0	34 (23.1)	1 (0.7)
Dry skin	24 (22.2)	1 (0.9)	0	0	0	0	26 (17.7)	1 (0.7)
Arthralgia	21 (19.4)	5 (4.6)	2 (10.0)	1 (5.0)	0	0	23 (15.6)	6 (4.1)
Palmar-plantar erythrodysesthesia syndrome	22 (20.4)	6 (5.6)	1 (5.0)	0	0	0	23 (15.6)	6 (4.1)
Constipation	21 (19.4)	0	1 (5.0)	0	0	0	22 (15.0)	0
Hypophosphatemia	17 (15.7)	11 (10.2)	2 (10.0)	2 (10.0)	0	0	19 (12.9)	13 (8.8)
Vomiting	15 (13.9)	1 (0.9)	1 (5.0)	0	1 (5.9)	0	17 (11.6)	1 (0.7)
Pain in extremity	15 (13.9)	0	0	0	0	0	15 (10.2)	0
Weight decreased	11 (10.2)	1 (0.9)	3 (15.0)	0	0	0	14 (9.5)	1 (0.7)
Hyponatremia	3 (2.8)	1 (0.9)	3 (15.0)	3 (15.0)	2 (11.8)	0	8 (5.4)	4 (2.7)


FGF, fibroblast growth factor; FGFR, FGF receptor; TEAE, treatment-emergent adverse event.

^aTotal number includes two patients who did not have confirmed *FGF/FGFR* status by central laboratory testing and were not assigned to any cohort.

^bAll any-grade TEAEs occurring in \geq 10% and grade \geq 3 TEAEs occurring in \geq 2% of the total population are shown.



"That's pork—the meat of the pig. It makes an excellent substitute for tofu." SEARCH ID: CC43217 CARTOONCOLLECTIONS.COM





Beverages beer/ale chocolate drinks cocoa dark colas drinks made with milk canned iced teas beverages w. phosphate




Dairy Products cheese liquid nondairy creamer custard ice cream milk pudding cream soups most yogurt

Protein oysters sardines beef liver chicken liver fish roe organ meats



Other chocolate candy caramels oat bran muffin processed foods pizza brewer's yeast Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement




Inhibitory Activity of Futibatinib, Pemigatinib, Infigratinib, and Erdafitinib against Acquired Resistance Mutations in the FGFR2 Kinase Domain.

FGFR2 Mutation	Kinase Domain Region	Factor Change in IC ₅₀ vs. Wild-Type FGFR2					
	-	Futibatinib Pemigatinib Infigratinib Er					
Wild-type	—	1	1	1	1		
N550D	Regulatory triad	2	102	81	10		
N550K	Regulatory triad	8	164	68	13		
V563L		3	5	14	1		
V565I	Gatekeeper	4	42	>236	1		
V565L	Gatekeeper	44	335	>236	23		
E566A	Regulatory triad	3	8	12	1		
E566G	Regulatory triad	2	6	10	1		
K642I	Regulatory triad	2	20	15	22		
K642R	Regulatory triad	2	7	16	1		
K660M	Activation loop	5	23	63	19		

Goyal L et al. N Engl J Med2023;388:228-239



Duration and Type of Response, Progression-free Survival, and Overall Survival among Patients Who Received Futibatinib.



Goyal L et al. N Engl J Med2023;388:228-239



HER2 Expression in BTCs

- In BTCs, HER2 overexpression, gene amplification, or both have been reported in several studies, and HER2-positive rates in GBC, ECC, and ICC are estimated to be 30%, 10–20%, and 5%, respectively.¹
- Through our preliminary study, we confirmed that the HER2 expression patterns in BTCs are more similar to those of gastric cancer than breast cancer, including heterogeneity.
- We also recently reported on the HER2 expression status according to the guidelines for HER2 testing in gastroesophageal adenocarcinoma in 454 cases (Table).²

	ICC	ЕСС-Вр	ECC-Bd	GBC	AVC
HER2-positive rate (%)	3.7	3.0	18.5	31.3	16.4


1. Cancer Discov 2017;7:943-62. 2. Hum Pathol 2020;105:9.

Screening Study (HERB preSCR)


- BTC pts were screened by central pathological examination using IHC and ISH in archival tissue at the SCRUM-Japan 30 sites into HER2-positive (defined as IHC 3+ or IHC 2+/ISH +), HER2-low-expressing (defined as IHC/ISH status of 0/+, 1+/-, 1+/+, or 2+/-), or HER2-negative (defined as IHC/ISH status of 0/-) pts.
- Between Mar 2019 and Mar 2020, 300 BTC pts were screened. Of the 296 pts with IHC and ISH results, 61 pts had HER2-positive, and 120 pts had HER2-low-expressing tumors.


n=296	Positive (n=61, 20.6%)			Low-expressing (n=120, 40.5%)				Neg. (38.9%)
IHC	3+		2+		1+		0	
ISH	+	-	+	-	+	-	+	-
n	17	0	44	53	8	49	10	115

Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Adenocarcinoma




Published in: Vikas Ostwal; Sarika Mandavkar; Prabhat Bhargava; Sujay Srinivas; Akhil Kapoor; Omshree Shetty; Sadhana Kannan; Deepair Chaugure; Rajsnree Patir; Ivianair Parulekar; Chaitair Ivasnikkar; Suman Kumar Ankathi; Akshay Dwarka Baheti; Daksha Mehta; Rajiv Kumar Kaushal; Subhash Yadav; Aekta Shah; Shraddha Patkar; Mahesh Goel; Anant Ramaswamy JCO 2023 11-9 DOI: 10.1200/JCO.23.01193 Copyright © 2023 American Society of Clinical Oncology Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study





Published in: Yoshiaki Nakamura; Nobumasa Mizuno; Yu Sunakawa; Jean-Luc Canon; Matthew D. Galsky; Erika Hamilton; Hidetoshi Hayashi; Guy Jerusalem; Seung Tae Kim; Keun-Wook Lee; Lionel Aurelien Kankeu Fonkoua; Bradley J. Monk; Danny Nguyen; Do-Youn Oh; Alicia Okines; David M. O'Malley; Paula Pohlmann; Martin Reck; Sang Joon Shin; Kazuki Sudo; Shunji Takahashi; Cedric Van Marcke; Evan Y. Yu; Roman Groisberg; Jorge Ramos; Sherry Tan; Thomas E. Stinchcombe; Tanios Bekaii-Saab JCO 2023 09-26 DOI: 10.1200/JCO.23.00606 Copyright © 2023 American Society of Clinical Oncology


Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial




Published in: Akihiro Ohba; Chigusa Morizane; Yasuyuki Kawamoto; Yoshito Komatsu; Makoto Ueno; Satoshi Kobayashi; Masafumi Ikeda; Mitsuhito Sasaki; Junji Furuse; Naohiro Okano; Nobuyoshi Hiraoka; Hiroshi Yoshida; Aya Kuchiba; Ryo Sadachi; Kenichi Nakamura; Naoko Matsui; Yoshiaki Nakamura; Wataru Okamoto; Takayuki Yoshino; Takuji Okusaka JCO 2024 08-5 DOI: 10.1200/JCO.23.02010


Copyright © 2024 American Society of Clinical Oncology

Zanidatamab for *HER2*-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study






Zanidatamab: A Biparatopic Bispecific Antibody for HER2-Expressing Cancers



Reduced cell survival and

proliferation




Complement activation C3b MAC

Complement-dependent cytotoxicity

cytotoxicity

Tumor cell death



How birds see the world.